{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:59:11Z","timestamp":1791176351795,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40265-022-01724-0","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T10:28:04Z","timestamp":1653128884000},"page":"933-940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Ganaxolone: First Approval"],"prefix":"10.1007","volume":"82","author":[{"given":"Yvette N.","family":"Lamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"key":"1724_CR1","unstructured":"Marinus Pharmaceuticals. Marinus announces successful clinical trial results and declares CDKL5 disorder its lead pediatric orphan epilepsy program for ganaxolone [media release]. 12 Sep 2017."},{"key":"1724_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s11689-021-09384-z","volume":"13","author":"HE Olson","year":"2021","unstructured":"Olson HE, Daniels CI, Haviland I, et al. Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder. J Neurodev Disord. 2021;13:4. https:\/\/doi.org\/10.1186\/s11689-021-09384-z.","journal-title":"J Neurodev Disord"},{"key":"1724_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2019.02.015","volume":"97","author":"HE Olson","year":"2019","unstructured":"Olson HE, Demarest ST, Pestana-Knight EM, et al. Cyclin-dependent kinase-like 5 deficiency disorder: clinical review. Pediatr Neurol. 2019;97:18\u201325.","journal-title":"Pediatr Neurol"},{"key":"1724_CR4","unstructured":"US Food & Drug Administration. FDA approves drug for treatment of seizures associated with rare disease in patients two years of age and older. 2022. https:\/\/www.fda.gov\/. Accessed 28 Apr 2022."},{"key":"1724_CR5","unstructured":"Marinus Pharmaceuticals. Marinus Pharmaceuticals completes in vivo M2 metabolite study and provides European regulatory update [media release]. 3 Feb 2022."},{"key":"1724_CR6","unstructured":"Marinus Pharmaceuticals, Inc. ZTALMY\u00ae (ganaxolone) oral suspension, CXX [pending controlled substance scheduling]: US prescribing information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215904s000lbl.pdf. Accessed 28 Apr 2022."},{"key":"1724_CR7","unstructured":"Marinus Pharmaceuticals. Marinus Pharmaceuticals announces exclusive collaboration with Orion Corporation for European commercialization of ganaxolone [media release]. 3 Aug 2021."},{"key":"1724_CR8","unstructured":"Marinus Pharmaceuticals. Marinus awarded BARDA contract to develop IV ganaxolone for treatment of refractory status epilepticus caused by nerve agent exposure [media release]. 15 Sep 2020."},{"key":"1724_CR9","unstructured":"Marinus Pharmaceuticals. US Securities and Exchange Commission Form 10-K. 2022. https:\/\/www.sec.gov\/. Accessed 28 Apr 2022."},{"key":"1724_CR10","unstructured":"Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc. enters into use agreement with CyDex Pharmaceuticals, Inc. for use of Captisol\u00ae for ganaxolone IV [media release]. 12 Aug 2014."},{"issue":"3","key":"1724_CR11","first-page":"1284","volume":"280","author":"RB Carter","year":"1997","unstructured":"Carter RB, Wood PL, Wieland S, et al. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. J Pharmacol Exp Ther. 1997;280(3):1284\u201395.","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"1724_CR12","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/S0028-3908(99)00190-2","volume":"39","author":"M Gasior","year":"2000","unstructured":"Gasior M, Ungard JT, Beekman M, et al. Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: comparison with diazepam and valproate. Neuropharmacology. 2000;39(7):1184\u201396.","journal-title":"Neuropharmacology"},{"key":"1724_CR13","unstructured":"Marinus Pharmaceuticals. Ganaxolone: mechanism of action and pharmacology. In: 74th American Epilepsy Society (Virtual), December 4\u20138, 2020. 2020."},{"issue":"7","key":"1724_CR14","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/j.1528-1157.2000.tb00244.x","volume":"41","author":"S Lipt\u00e1kov\u00e1","year":"2000","unstructured":"Lipt\u00e1kov\u00e1 S, Vel\u00edsek L, Vel\u00edskov\u00e1 J, et al. Effect of ganaxolone on flurothyl seizures in developing rats. Epilepsia. 2000;41(7):788\u201393.","journal-title":"Epilepsia"},{"issue":"3","key":"1724_CR15","first-page":"1241","volume":"295","author":"DS Reddy","year":"2000","unstructured":"Reddy DS, Rogawski MA. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J Pharmacol Exp Ther. 2000;295(3):1241\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1724_CR16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1124\/jpet.118.252155","volume":"368","author":"MS Saporito","year":"2019","unstructured":"Saporito MS, Gruner JA, DiCamillo A, et al. Intravenously administered ganaxolone blocks diazepam-resistant lithium-pilocarpine-induced status epilepticus in rats: comparison with allopregnanolone. J Pharmacol Exp Ther. 2019;368(3):326\u201337.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"1724_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1474-4422(22)00077-1","volume":"21","author":"EM Pestana Knight","year":"2022","unstructured":"Pestana Knight EM, Amin S, Bahi-Buisson N, et al. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2022;21(5):417\u201327.","journal-title":"Lancet Neurol"},{"key":"1724_CR18","unstructured":"Demarest S, Aimetti A, Rybak E, et al. Effect of ganaxolone on quality of life in children with the CDKL5 deficiency disorder [abstract no. 3.279]. In: 75th Annual Meeting of the American Epilepsy Society. 2021."},{"key":"1724_CR19","unstructured":"Miller I, Nocera R, Aimetti A. Ganaxolone treatment in patients with CDKL5 deficiency disorder with comorbid Lennox-Gastaut syndrome: a post hoc analysis from the Marigold study [abstract no. 2.098 plus poster]. In: 75th Annual Meeting of the American Epilepsy Society. 2021."},{"key":"1724_CR20","doi-asserted-by":"crossref","unstructured":"Olson H, Valappil AN, Rybak E, et al. Extended duration safety and efficacy of adjunctive ganaxolone treatment in patients with CDKL5 deficiency disorder: 8-month minimum open-label extension follow-up [abstract no. 2.217 plus poster]. In: 75th Annual Meeting of the American Epilepsy Society. 2021.","DOI":"10.1212\/WNL.98.18_supplement.3540"},{"key":"1724_CR21","unstructured":"Data on file, Marinus Pharmaceuticals, 2022."},{"key":"1724_CR22","unstructured":"Marinus Pharmaceuticals. Marinus Pharmaceuticals phase 2 clinical trial data show long-term effectiveness of ganaxolone in reducing seizure frequency in CDKL5 deficiency disorder patients [media release]. 5 Dec 2018."},{"key":"1724_CR23","unstructured":"Sullivan J, Gunning B, Zafar M, et al. Phase 2, placebo-controlled clinical study of oral ganaxolone in PCDH19-clustering epilepsy [abstract no. 3.281 plus poster]. In: 75th Annual Meeting of the American Epilepsy Society. 2021."},{"key":"1724_CR24","doi-asserted-by":"crossref","unstructured":"Koenig MK, Mahalingam R, Peters J, et al. Phase 2 open-label clinical study evaluating oral ganaxolone for the treatment of seizures associated with tuberous sclerosis complex [abstract no. 2.412 plus poster]. In: 75th Annual Meeting of the American Epilepsy Society. 2021.","DOI":"10.1212\/WNL.98.18_supplement.3519"},{"issue":"Suppl. 3","key":"1724_CR25","first-page":"348","volume":"62","author":"H Vaitkevicius","year":"2021","unstructured":"Vaitkevicius H, Ramsay E, Swisher CB, et al. Phase 2 open-label, dose-finding study of intravenous ganaxolone for the treatment of refractory status epilepticus. Epilepsia. 2021;62(Suppl. 3):348.","journal-title":"Epilepsia"},{"issue":"1","key":"1724_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s11689-017-9207-8","volume":"9","author":"A Ligsay","year":"2017","unstructured":"Ligsay A, Van Dijck A, Nguyen DV, et al. A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome. J Neurodev Disord. 2017;9(1):26.","journal-title":"J Neurodev Disord"},{"key":"1724_CR27","unstructured":"Gasior M, Hulihan J, Miller I. Aggregated safety and tolerability experience from the ganaxolone development program [abstract no. 2.205 plus poster]. In: 75th Annual Meeting of the American Epilepsy Society. 2021."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01724-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01724-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01724-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T18:01:25Z","timestamp":1727287285000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01724-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,21]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1724"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01724-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,21]]},"assertion":[{"value":"21 May 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yvette Lamb is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}